Intravenous infusion dosage form

US10869867B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-10869867-B2
Application numberUS-201615550638-A
CountryUS
Kind codeB2
Filing dateFeb 12, 2016
Priority dateFeb 13, 2015
Publication dateDec 22, 2020
Grant dateDec 22, 2020

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention relates to an intravenous infusion dosage form of pemetrexed or its pharmaceutically acceptable salt, having long term stability.

First claim

Opening claim text (preview).

The invention claimed is: 1. An intravenous infusion dosage form comprising a) a composition consisting essentially of pemetrexed or its pharmaceutically acceptable salt present at a concentration ranging from about 0.7 mg/ml to about 21 mg/ml, an osmogent and an inert gas in solution in a parenteral aqueous vehicle, the solution having a volume ranging from about 50 ml to 1000 ml, b) a flexible infusion container containing the composition of (a) and an inert gas in a headspace of the infusion container, c) a second container surrounding the flexible infusion container with an inert gas or vacuum in the space between the flexible infusion container and the second container, wherein the total impurities are less than 2.0% by weight. 2. The intravenous infusion dosage form of claim 1 , wherein the dosage form is subjected to moist heat sterilization. 3. The intravenous infusion dosage form of claim 1 , wherein the second container is made up of aluminum. 4. The intravenous infusion dosage form of claim 1 , wherein the inert gas is selected from nitrogen, argon or helium. 5. The intravenous infusion dosage form of claim 1 , wherein the dosage form is prepared by a method comprising the steps of a) dissolving pemetrexed or its pharmaceutically acceptable salt and an osmogent in a parenteral aqueous vehicle, b) filling the solution of step (a) into a flexible infusion container, c) sealing the filled flexible infusion container, d) surrounding the flexible infusion container by a second container and sealing the second container, e) subjecting the container of step (d) to moist heat sterilization, wherein in each of the above steps, low oxygen conditions are maintained in the solution and/or in the head space of the flexible infusion container and in the space between the flexible infusion container and the second container. 6. The intravenous infusion dosage form of claim 5 , wherein the method further comprises maintaining the dosage form of step (d) for at least 12 hours prior to step (e). 7. The intravenous infusion dosage form of claim 5 , wherein the increase in total impurities of Pemetrexed during moist heat sterilization is less than 0.2%. 8. An intravenous infusion dosage form comprising: a) a composition consisting essentially of pemetrexed or its pharmaceutically acceptable salt present at a concentration ranging from about 0.7 mg/ml to about 21 mg/ml, an osmogent and an inert gas in solution in a parenteral aqueous vehicle, the solution having a volume ranging from about 50 ml to 1000 ml, b) a rigid infusion container containing the composition of (a) and an inert gas in a headspace of the infusion container, wherein the dosage form is subjected to moist heat sterilization and wherein the total impurities are less than 2.0% by weight. 9. The intravenous infusion dosage form of claim 8 wherein the infusion container is surrounded by a second container, with an inert gas or vacuum in the space between the infusion container and the second container.

Assignees

Inventors

Classifications

  • A61K31/519Primary

    ortho- or peri-condensed with heterocyclic rings · CPC title

  • A61J1/10Primary

    Bag-type containers · CPC title

  • Inorganic compounds · CPC title

  • Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00) · CPC title

  • Filling medical containers such as ampoules, vials, syringes or the like · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US10869867B2 cover?
The present invention relates to an intravenous infusion dosage form of pemetrexed or its pharmaceutically acceptable salt, having long term stability.
Who is the assignee on this patent?
Sun Pharmaceutical Ind Ltd
What technology area does this patent fall under?
Primary CPC classification A61K31/519. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Dec 22 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).